Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon May 28, 2022 11:32am
287 Views
Post# 34714387

Andrew Schutte increases position in Replicel

Andrew Schutte increases position in Replicel

News Release from Stockwatch May 28th

"Following the Transaction, Mr. Schutte owned the following securities: (i) 6,079,604 Shares held directly; (ii) 250,000 class A preference shares held directly to purchase an additional 303,030 Shares; (iii) 355,000 stock options held directly to purchase an additional 355,000 Shares; and (iv) 1,613,901 warrants held directly to purchase an additional 1,613,901 Shares. After the issuance of the Shares pursuant to the Transaction, Mr. Schutte directly and indirectly owned and controlled 8,351,535 Shares, on a partially diluted basis (assuming conversion of the class A preference shares and exercise of all stock options and warrants), which represents 18.55% of the issued and outstanding Shares as of May 4, 2022, based on the aggregate of 45,021,496 Shares, which consists of: (i) 42,749,565 Shares outstanding as of May 4, 2022, (ii) 303,030 Shares that may be issuable on conversion of class A preference shares, (iii) 355,000 Shares that may be issuable on exercise of options and (iv) 1,613,901 Shares that may be issuable on exercise of warrants."

This is very interesting :
Andrew Schutte: 8,351,535 shares
Mainpointe:        3,986,687 shares
Total                12,338,222 shares 

Replicel shares outstanding 45,021,496

12,338,222/45,021,496 = 27.4% ownership of Replicel

Possibly in this next private placement which closes on June 6 either Andrew Schutte or Mainpointe may add more shares.

What conclusions can you draw from this.  Let your imagination run wild ! 


 

Andrew Schutte has issued this news release pursuant to Part 3.1 of National Instrument 62-103, The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, with respect to RepliCel Life Sciences Inc. Mr. Schutte is a director of the company. On May 4, 2022, the Acquiror acquired 2,102,303 units (the "Units") from the Company on a private placement basis at a price of $0.18 per Unit for proceeds of $378,414.54 pursuant to a private placement subscription agreement (the "Transaction"). Each Unit consists of one common share (each, a "Share") and one-half of one share purchase warrant (each whole warrant, a "Warrant"). One Warrant entitles the holder thereof to purchase one additional Share of the Company at a price of $0.40 per Share until May 4, 2025.

Prior to the Transaction, Mr. Schutte owned the following securities: (i) 3,977,301 Shares held directly; (ii) 250,000 class A preference shares held directly to purchase an additional 303,030 Shares; (iii) 30,000 stock options held directly to purchase an additional 30,000 Shares and 562,750 warrants held directly to purchase an additional 562,750 Shares. Prior to the Transaction, Mr. Schutte directly owned 5,198,081 Shares, on a partially diluted basis (assuming conversion of the class A preference shares and exercise of all stock options), which represented 10.32% of the issued and outstanding Shares as of May 3, 2022, based on 39,751,875 Shares, which consists of: (i) 38,531,095 Shares outstanding as of May 3, 2022, (ii) 303,030 Shares that may be issuable on conversion of class A preference shares, (iii) 355,000 Shares that may be issuable on exercise of options and (iv) 562,750 Shares that may be issuable on exercise of warrants.

Following the Transaction, Mr. Schutte owned the following securities: (i) 6,079,604 Shares held directly; (ii) 250,000 class A preference shares held directly to purchase an additional 303,030 Shares; (iii) 355,000 stock options held directly to purchase an additional 355,000 Shares; and (iv) 1,613,901 warrants held directly to purchase an additional 1,613,901 Shares. After the issuance of the Shares pursuant to the Transaction, Mr. Schutte directly and indirectly owned and controlled 8,351,535 Shares, on a partially diluted basis (assuming conversion of the class A preference shares and exercise of all stock options and warrants), which represents 18.55% of the issued and outstanding Shares as of May 4, 2022, based on the aggregate of 45,021,496 Shares, which consists of: (i) 42,749,565 Shares outstanding as of May 4, 2022, (ii) 303,030 Shares that may be issuable on conversion of class A preference shares, (iii) 355,000 Shares that may be issuable on exercise of options and (iv) 1,613,901 Shares that may be issuable on exercise of warrants.

Mr. Schutte acquired the securities of the Company for investment purposes. Depending on economic or market conditions or matters relating to the Company, Mr. Schutte may choose to either acquire additional securities or dispose of securities of the Company.

A copy of Mr. Schutte's early warning report will appear on the Company's profile on SEDAR at www.sedar.com and may also be obtained by contacting Andrew Schutte at 502.709.7544.


<< Previous
Bullboard Posts
Next >>